Shattuck Labs, Inc.
STTK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001680367
No open-market purchases or sales by Shattuck Labs, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $581.3M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:56 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $48.8M (4880.9% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Mar 27, 2025 | Feb 29, 2024 | Feb 23, 2023 | Mar 15, 2022 |
| Revenue | $1.00M | $5.72M | $1.66M | $652.0K | $30.0M |
| Operating expenses | $52.5M | $86.3M | $93.6M | $104.0M | $75.3M |
| Research and development | $35.3M | $67.2M | $74.3M | $82.9M | $56.6M |
| Selling, general and administrative | $17.2M | $19.1M | $19.3M | $21.1M | $18.7M |
| Operating income | -$51.5M | -$80.6M | -$92.0M | -$103.3M | -$45.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$48.8M | -$75.4M | -$87.3M | -$101.9M | -$45.0M |
| EPS, basic | $-0.70 | $-1.49 | $-2.05 | $-2.41 | $-1.07 |
| EPS, diluted | $-0.70 | $-1.49 | $-2.05 | $-2.41 | $-1.07 |
| Weighted shares, basic | 69.6M | 50.8M | 42.6M | 42.4M | 42.0M |
| Weighted shares, diluted | 69.6M | 50.8M | 42.6M | 42.4M | 42.0M |
| Margins and growth | |||||
| Operating margin | -5150.8% | -1408.3% | -5549.6% | -15848.0% | -150.8% |
| Net margin | -4880.9% | -1318.1% | -5268.4% | -15635.7% | -149.8% |
| Revenue growth, year over year | −82.5% | +245.3% | +154.1% | −97.8% | +202.2% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Mar 27, 2025 | Feb 29, 2024 | Feb 23, 2023 | Mar 15, 2022 |
| Cash and equivalents | $54.2M | $57.4M | $125.6M | $47.4M | $92.3M |
| Total current assets | $82.5M | $79.2M | $143.2M | $184.6M | $288.3M |
| Property, plant and equipment | $6.11M | $9.81M | $13.8M | $17.7M | $9.94M |
| Total assets | $91.0M | $91.0M | $159.6M | $205.3M | $298.6M |
| Accounts payable | $2.10M | $2.42M | $1.59M | $7.17M | $10.0M |
| Total current liabilities | $7.05M | $8.92M | $11.5M | $25.0M | $24.6M |
| Total liabilities | $8.64M | $11.4M | $14.9M | $29.2M | $26.8M |
| Shareholders' equity | $82.4M | $79.6M | $144.7M | $176.2M | $271.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Mar 27, 2025 | Feb 29, 2024 | Feb 23, 2023 | Mar 15, 2022 |
| Operating cash flow | -$39.9M | -$60.5M | -$81.2M | -$94.5M | -$57.1M |
| Capital expenditures | $71.0K | $59.0K | $407.0K | $11.6M | $7.93M |
| Free cash flow | -$40.0M | -$60.6M | -$81.6M | -$106.1M | -$65.0M |
| Depreciation and amortization | $3.70M | $3.80M | $4.00M | $3.10M | $1.40M |
| Stock-based compensation | $7.00M | $9.55M | $6.94M | $6.46M | $5.47M |
| Investing cash flow | -$7.89M | -$8.51M | $110.9M | $49.4M | -$10.4M |
| Financing cash flow | $44.6M | $787.0K | $48.6M | $171.0K | $1.93M |
| Net change in cash | -$3.19M | -$68.2M | $78.2M | -$44.9M | -$65.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 699.5% | 166.9% | 418.8% | 991.1% | 18.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 101.8M | +60.9% | SEC |
| Aug 7, 2026 | 100.4M | +109.5% | SEC |
| Apr 30, 2026 | 76.7M | +60.1% | SEC |
| Feb 26, 2026 | 71.6M | +49.4% | SEC |
| Oct 23, 2025 | 63.3M | +32.6% | SEC |
| Aug 7, 2025 | 47.9M | +0.4% | SEC |
| Apr 21, 2025 | 47.9M | +0.7% | SEC |
| Apr 1, 2025 | 47.9M | +0.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.